

14th Asia Pacific

ONCOLOGISTS ANNUAL MEETING

November 20-22, 2017 Melbourne, Australia

The angiogenic properties of NSC-631570

Wassil Nowicky

Ukrainian Anti-Cancer Institute, Austria

Another important feature of medical preparation NSC-631570 after its selective effect (in therapeutic dosage it kills only cancer cells leaving the healthy cells undamaged) is the inhibition of the formation of the new blood vessels supplying a tumor. Due to these anti-angiogenic properties NSC-631570 administered before surgery brings about better demarcation of the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been confirmed in breast cancer studies. In *in vitro* tests; NSC-631570 inhibited in a dose dependent manner, the proliferation of human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation model. This inhibition of the neoangiogenesis prevents the metastasis formation as well.

Biography

Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He is the author of over 300 scientific articles dedicated to cancer research. He is the Member of the New York Academy of Sciences, Member of the European Union for Applied Immunology and the American Association for Scientific Progress, Honorary Doctor of the Janka Kupala University in Hrodno, Doctor Honoris Causa of the Open International University on Complex Medicine in Colombo, Honorary Member of the Austrian Society. He has received the award for Merits of National Guild of Pharmacists of America, the award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.

dr.nowicky@yahoo.de

Notes: